Drug intelligence / Profile preview

dalteparin + unfractionated heparin

Development stage: Unknown
Lead developer: Pfizer
Modality: Small Molecules
Administration: Subcutaneous, Intravenous

Overview

This is a combination of dalteparin (a low molecular weight heparin) and unfractionated heparin (UFH). Both medications are anticoagulants that work by potentiating the activity of antithrombin III, though with different specificities. Dalteparin preferentially inactivates factor Xa, while unfractionated heparin inhibits both factor Xa and thrombin. This combination is not typically used clinically as a fixed combination product, as these medications are generally used separately based on specific clinical indications.

Targets

ATIII (Antithrombin III)

Beyond the preview

Go deeper on dalteparin + unfractionated heparin.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on dalteparin + unfractionated heparin.

Explore the full profile